Compare Entegris Inc (ENTG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Zimmer Biomet Holdings Inc — how do they compare? Entegris Inc trades at $165.79 (market cap $24.78B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Entegris Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ENTG | ZBH | |
|---|---|---|
Market Cap | $24.78B | $16.95B |
Volume | 2,648,320 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $184.00 | $103.98 |
52-Week Low | $68.80 | $79.58 |
Typical Hold Time | 41 Days | 89 Days |
Enterprise Value | $27.99B | $24.02B |
Dividend Yield | 0.25% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.48% today but maintains strong technical momentum with bullish moving averages and key support at $158. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.93 exceeding expectations by 13%. Revenue remains stable at $3.2B annually while net margins improved to 9.18% in 2026. Recent institutional buying from BlackRock and Baird Financial Group signals confidence in the semiconductor materials supplier.
ENTG presents a compelling growth story driven by AI semiconductor demand and operational improvements, with analyst consensus targeting 12.5% upside to $182.43. However, elevated valuation multiples (P/E 81.1, EV/EBITDA 31.7) and high long-term debt of $3.98B create vulnerability to sector downturns. The stock's performance hinges on continued execution amid semiconductor cycle volatility.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
